Fructose is a big contributor to the development of non-alcoholic fatty liver disease
(NAFLD). Inhibiting ketohexokinase (KHK), the enzyme catalyzing the first committed step in
fructose metabolism, is thought to reduced intrahepatic lipid (IHL) content. Pharmacological
inhibition of KHK resulted in a decrease in IHL content in NAFLD patients, but additional
health effects are still unknown. In this study the investigators aim to look at additional
health effects following KHK inhibition (KHKi).